| Description | Peptide5 acetate reduces animal swelling, astrogliosis, and neuronal cell death after spinal cord injury. Peptide5 acetate significantly reduces the degree of spinal cord injury (SCI) in a rodent ex vivo model. |
| In vitro | 使用Peptide5 acetate 处理能够同时降低Cx43的水平和胶质纤维酸性蛋白(GFAP)阳性星形胶质细胞的数量，并以浓度依赖和时间依赖的方式减少NeuN和SMI-32阳性神经元的损失。此外，Peptide5 acetate 在减轻[2]肿胀方面显示出更显著的效果。 |
| In vivo | Peptide5 acetate 可用于治疗创伤性脊髓损伤大鼠[2]。 |
| molecular weight | N/A |
| Storage | store at low temperature,store under nitrogen,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50.00 mg/mL |
| References | 1. Yilin Mao, et al. Characterisation of Peptide5 systemic administration for treating traumatic spinal cord injured rats. Exp Brain Res. 2017 Oct;235(10):3033-3048. 2. Simon J O'Carroll, et al. Connexin 43 mimetic peptides reduce swelling, astrogliosis, and neuronal cell death after spinal cord injury. Cell Commun Adhes. 2008 May;15(1):27-42. |